This report provides comprehensive information on the therapeutic development for Thalassemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Thalassemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

Introduction
Thalassemia Overview
Therapeutics Development
Pipeline Products for Thalassemia - Overview
Pipeline Products for Thalassemia - Comparative Analysis
Thalassemia - Therapeutics under Development by Companies
Thalassemia - Therapeutics under Investigation by Universities/Institutes
Thalassemia Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thalassemia - Products under Development by Companies
Thalassemia - Products under Investigation by Universities/Institutes
Thalassemia - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Acino Pharma AG
Agios Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
Bluebird bio, Inc.
Editas Medicine, Inc.
Emmaus Medical, Inc.
Errant Gene Therapeutics, LLC
Gamida Cell Ltd.
Incyte Corporation
Ionis Pharmaceuticals, Inc.
IRBM Science Park SpA
Johnson & Johnson
Kiadis Pharma B.V.
La Jolla Pharmaceutical Company
Merck & Co., Inc.
PharmaEssentia Corporation
Protagonist Therapeutics Inc.
Sangamo BioSciences, Inc.

For more information visit http://www.researchandmarkets.com/research/57clfh/thalassemia

You have no rights to post comments

Suche

Cookies erleichtern die Bereitstellung unserer Dienste. Mit der Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies verwenden.
Weitere Informationen Ok Ablehnen